In its push to backstop sales of blockbuster Soliris, Alexion has touted its better-than-expected success at switching patients to follow-up drug Ultomiris. But if switching to the newer med is going ...
In the quest to match its predecessor Soliris, Alexion's Ultomiris just notched a win in the autoimmune disorder myasthenia gravis. Alexion is trumpeting data showing Ultomiris met its primary ...
Smarting from a patent defeat for cash cow Soliris in Europe, Alexion has dulled the pain with a phase 3 readout that sets up new filings for follow-up Ultomiris. The top-line data comes from a study ...
When it comes to new drugs, how much are we willing to pay for innovation? That question, touched on by Craig Garthwaite and Benedic Ippolito in their First Opinion on drug prices, deserves a deeper ...
“ ULTOMIRIS is a compelling new therapy for patients with PNH. It has met the high bar for efficacy and safety established by SOLIRIS and has a four times longer dosing interval,” said Ilene Weitz, ...
BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced plans to initiate a global Phase 3 study to investigate ULTOMIRIS® (ravulizumab-cwvz) in a subset of adults with ...
BOSTON -- (EUREKALERT!) -- Alexion Pharmaceuticals, Inc. today announced the first conference presentation of the topline Phase 3 data for ULTOMIRIS ® (ravulizumab), the first and only long-acting C5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results